Yamada Bee Company, Inc.

Tohoku University

Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

National Cancer Center

Kumamoto University

National University Corporation Kumamoto University

Tomoki Tatefuji

Takashi Asama

Daisuke Matsuura

Tomoki Ikuta

Ken Hashimoto

Hironori Motoki

Hiroshi Yamauchi

Shogo Misumi

Shinobu Fukushima

Hiroko Tani

Hitoshi Shirakawa

Hiroshi Inooka

Kenichi Yoshioka

Masao Ikeda

The present invention provides a mucosal immunomodulator comprising, as an active ingredient, at least one selected from the group consisting of compounds represented by the following formula (1), compounds represented by the following formula (2) and compounds represented by the following formula (3), and salts thereof. 

Mucosal immunomodulator

Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C.

Genome stability enhancer

Disclosed are: a lactic acid bacterium belonging to, the bacterium having a higher IgA production inducing activity than that ofstrain GG (ATCC53103), and a lower mitogenic activity and a lower IL-2 production inducing activity than those ofstrain EGD; and a food composition, a pharmaceutical composition, a cosmetic composition, an immunostimulant for preventing the infection by pathogens or viruses that invade through the respiratory or esophageal mucosa, and an intestinal immunostimulant for preventing or alleviating food poisoning, each of which contains the lactic acid bacterium or treated cells of the lactic acid bacterium.

Lactic acid bacterium having IgA production promoting activity, and use thereof

Disclosed is a semi-solid pharmaceutical agent containing a stabilized proteinaceous bioactive substance prepared by successively mixing an oligosaccharide and an aqueous solution of a proteinaceous bioactive substance, and kneading the resultant solids with an oil or fat base. The pharmaceutical handles with ease because it is readily administered to the body through percutaneous and permucosal route which are safer and less in pain administration routes than other conventional administrations.

Semi-solid pharmaceutical agent and process for producing the same

Growing community of inventors

Okayama, Japan

Tomoki Tatefuji